- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Potenza Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 2014
Status: Acquired
BioCentury | Nov 3, 2020
Product Development
Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas
EMA reviewing filgotinib for ulcerative colitisGilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said EMA is reviewing its MAA for Jyseleca filgotinib to treat
BioCentury | Mar 24, 2020
Deals
With bispecifics deal, Astellas becomes CytomX’s first new partner since 2017
BioCentury | Dec 27, 2019
Product Development
Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform
Xyphos’ animal data and focus on its CAR T switch platform paid off with Astellas takeout
BioCentury | Nov 20, 2019
Financial News
Werewolf debuts with $56M to develop tumor-activated biologics
BioCentury | Jul 12, 2018
Translation in Brief
Reviving NK cells
How targeting TIGIT unleashes the cancer-fighting activity of NK cells
BioCentury | May 23, 2016
Finance
Venturing west
How newly formed Taiho Ventures plans to spend its $50 million fund
BioCentury | May 18, 2015
Finance
New (Bio)ventures at MPM
How MPM wants to deploy its new $400 million fund
Items per page:
1 - 10 of 13